


**Table S1:** Exemplary presentation of results of the statistical analysis.

P-value	Meaning	Statistical test	Exemplary statistical output
P	Correlation of T-cell subsets with age for healthy controls		Fig 1A, x=age, y=RTE-Tregs of ICOS <sup>+</sup> -Tregs p < 0.0001 (R -0.41, $\beta$ -0.04, t (113) = 4.85)
P	Correlation of T-cell subsets with age for SLE patients in remission	<b>Linear Regression</b> (according to Pearson)	Fig 1A, x=age, y=RTE-Tregs of ICOS <sup>+</sup> -Tregs p < 0.001 (R -0.39, $\beta$ -0.02, t (94) = 3.96)
P	Correlation of T-cell subsets with age for active SLE patients		Fig 1A, x=age, y=RTE-Tregs of ICOS <sup>+</sup> -Tregs P < 0.05 (R -0.47, $\beta$ -0.15, t (18) = 2.23)
P	Age independent differences between SLE patients in remission versus healthy controls	<b>Multiple Regression</b>	Fig 1A, x=age, y=RTE-Tregs of ICOS <sup>+</sup> -Tregs ↓P < 0.0001 (R=0.47, $\beta$ -0.64, f <sup>2</sup> = 0.29)
P	Age independent differences between active SLE patients versus healthy controls	(adjusted for age, centered on the mean)	Fig 1A, x=age, y=RTE-Tregs of ICOS <sup>+</sup> -Tregs ↑P < 0.001 (R=0.52, $\beta$ 1.06, f <sup>2</sup> = 0.38)
Δp	Differences in the slope of the regression lines between T-cell subsets of SLE patients in remission and healthy controls	<b>Comparison of regression lines</b>	Fig 3C, x= Ki67 <sup>+</sup> -cells of ICOS <sup>+</sup> -RTE-Tresps, y= RTE-Tresps of ICOS <sup>+</sup> -CD45RA <sup>+</sup> -Tresps (%) Δp < 0.01
Δp	Differences in the slope of the regression lines between T-cell subsets of active SLE patients and healthy controls		Fig 2C, x= Ki67 <sup>+</sup> -cells of ICOS <sup>+</sup> -RTE-Tregs, y= RTE-Tregs of ICOS <sup>+</sup> -CD45RA <sup>+</sup> -Tregs (%) Δp < 0.0001

Suppl. Fig. 1



**Scheme S1.** Gating Strategy. Positively isolated CD4<sup>+</sup>-T-helper cells were divided into CD4<sup>+</sup>CD127<sup>low/+</sup>-FoxP3<sup>+</sup>-Tregs (P1) and CD4<sup>+</sup>CD127<sup>+</sup>-FoxP3<sup>+</sup>-Tresps (P2) by gating fluorescence intensity of FoxP3 versus CD127 (A). ICOS<sup>+</sup>-Tregs/Tresps (P3, P4) and ICOS<sup>-</sup>-Tregs/Tresps (P5, P6) were gated by fluorescence activity of ICOS versus CD45RA (B and C). The percentages of ICOS<sup>+</sup>- and ICOS<sup>-</sup>-RTE-Tregs/Tresps (P7, P8, P9, P10), MN-Tregs/Tresps (P11, P12, P13, P14), CD31<sup>+</sup>-memory Tregs/Tresps

(P15, P16, P 17, P18) and CD31-memory Tregs/Tresps (P19, P20, P21, P22) were estimated by analyzing ICOS<sup>+</sup>-Tregs (P3), (D), ICOS<sup>+</sup>-Tregs (P5), (E), ICOS<sup>+</sup>-Tresps (P4), (F) and ICOS<sup>+</sup>-Tresps (P6), (G) for its fluorescence intensity of CD31 versus CD45RA. The Ki67 expression of ICOS<sup>+</sup>- or ICOS<sup>-</sup>-RTE, MN, CD31<sup>+</sup>-memory-Tregs and CD31<sup>+</sup>-memory-Tresps (P23-P26 and P27-P30), as well as Ki67 expression of ICOS<sup>+</sup>- or ICOS<sup>-</sup>-RTE, MN, CD31<sup>+</sup>-memory-Tresps and CD31<sup>+</sup>-memory-Tresps (P31-P34 and P35-P38) were estimated by analyzing the fluorescence intensity of CD31 versus Ki67 (H-K).